

APTORUM 

**OUR MISSION IS TO FACILITATE LIFE
SCIENCE INNOVATIONS TO SERVE UNMET
MEDICAL NEEDS**

Corporate Presentation


NASDAQ Global Market: APM



APTORUM


On 18th December 2018, Aptom Group Limited listed on the **NASDAQ** (ticker symbol: **APM**). IPO stock price is **USD 15.80**. Latest stock price is **over USD 28.00** with current market capital of over **USD 800 M**.

The Expanding Universe of Aptorum



THE MECHANISMS OF ALS-4


ANTI-GOLDEN PIGMENT AGENT




- Staphyloxanthin is the golden yellow pigment of *S. aureus*
- The pigment protects the bacteria against oxidative stress produced by our immune cells.
- ALS-4 is intended to suppress one of the key enzymes in the pigment production process
- *S. aureus* without pigments are more susceptible to host immune clearance

mBio [8(5): e01224, 2017]]

ALS-4 is intended to inhibit *S. aureus* pigment production with an IC₅₀ = 20nM




ALS-4 is observed to reduce bacterial load in mice



Acute treatment

Compound concentration: 1 mM;
Inoculum: 5 X 10⁶ per mouse
Treatment: twice for first 7 days,
First inject: 30 min after infection



Delayed treatment

Compound concentration: 1 mM;
Inoculum: 2 X 10⁷ per mouse
Treatment: twice for 7 days,
First inject: 11 days after infection

Diseases Associated with Microbiota

Digestive diseases

- *C. difficile* infection
- Colorectal cancer
- Inflammatory bowel disease
- Irritable bowel syndrome

Systemic diseases

- Obesity
- Diabetes
- Fatty liver
- Cardiovascular diseases
- Renal failure
- Depression
- Parkinsonism
- Autistic spectrum disorder


Our Strategy

1. Novel therapeutics to reduce amount of harmful **gut microbiota chemicals** that cause diseases
2. Act in gut with high affinity and specificity
3. Non-absorbable and free from systemic toxicity
4. Hundreds of metabolites for various clinical indications
5. Sustainable pipeline of unlimited therapeutic potentials


Smart-Act: Accelerating the Commercialization of Therapeutics

ACT- Accelerating the Commercialisation of Therapeutics

Traditional 3D



ACT 3D



¹<https://www.apuit.com/ebook-drug-discovery>

	Traditional 3D - Problems	Act 3D - Solutions
Time (years)	10-17 years ¹ Drug Discovery: 3-10 years ² Preclinical Development: 1 year Phase I: Several months ³ Phase II to market: 5.4 years ⁴	5-6.5 years Drug Discovery: 1-1.5 year Preclinical Development: may not needed Phase I: May not needed Phase II to market: 3.9 years ⁴
Cost	US\$2.6 billion ⁵	US\$ 33 million ⁶
Probability	↓ Low hit rate from discovery to commercialisation	↑ Higher probability of success 30% approval rate for repurposed drugs ⁷



DEVELOPMENT TIME



DEVELOPMENT COST



PROBABILITY OF SUCCESS

1 <http://www.totalbiopharma.com/2012/07/04/4-key-benefits-drug-repositioning/>

2 Estimated based on the overall development time of 10-17 years

3 <https://www.fda.gov/forpatients/approvals/drugs/ucm405622.htm>

4 Source: Drug Discov Today. 2012;17(13-14):660-4.

5 <https://www.the-scientist.com/features/repurposing-existing-drugs-for-new-indications-32285>


6 Source: Key cost drivers of pharmaceutical clinical trials in the United States (PDF), pg 5 (121), Oncology

<https://www.ncbi.nlm.nih.gov/pubmed/26908540>

7 <https://www.dcatvci.org/11-value-chain-insights/114-drug-repurposing-and-repositioning-making-new-out-of-old#>


LIFE EXAMPLES: Neuroblastoma

TARGET A




14 drugs identified

TARGET B





20 drugs identified

TARGET C



12 drugs identified



Wet Lab Validation	2019
Phase 3 Trial Done	2021
Regulatory Approval	2024
Commercialisation	2025
Total	6 years*



* Timeline is for illustrative purposes only. Actual timing and results may vary.

This slide merely shows an example of indications which the Smart-ACT may provide drug repurposing solutions. It is not a representation that we are actually developing a drug for this diseases and/or under the development timeline mentioned.

ACT- Accelerating the Commercialisation of Therapeutics



Dr. Justin WU
Clinical Advisor

Dr. Nishant AGRAWAL
Clinical Advisor

Dr. Henry CHAN
Clinical Advisor



Dr. Philip CHIU
Clinical Advisor



Dr. Vincent MOK
Clinical Advisor



Dr. Kenny YU
Clinical Advisor



Ms. Monique LEE
Head of Legal, Aptorum



Ms. Margaret BURKE
Patent Attorney



Mr. Sam YIP
Patent Attorney



Ms. Flora HO
Patent Agent




Mr. Johnny WONG
Patent Specialist



Mr. Tim HUANG
Patent Specialist

Clinical Validation



Mr. Geoffrey TIPTON
CTO, Aenco



Dr. Ka-Wai KWOK
Advisor



Mr. Issac CHEUNG
Full Stack Developer



Mr. Aaron REGALA
Business Analyst



Dr. Thomas LEE
Head of R&D, Aptorum



Dr. Albert CHOW
CEO, Aptorum Pharmaceutical Development



Dr. Daniel POON
Senior Project Leader



Mr. Junzhe HUANG
Manager



Dr. Kwok CHOW
Advisor




Mr. Austin FREEDMAN
Advisor



Dr. Herman LAM
Advisor

ACT - Accelerating the Commercialisation of Therapeutics

ACT THERAPEUTIC PORTFOLIO VALUATION VERSUS PROJECTED CLINICAL ASSETS: Commercialisation + Out-Licensing Monetization Strategies



¹Smart Pharma internal estimates based on model assumptions. Details available upon request.


²<https://www.ncbi.nlm.nih.gov/pubmed/26908540>

Value projections are illustrative only. All estimates and forward-looking projections are based on modeled assumptions, which we believe to be reasonable, and evidence based where applicable. However, such assumptions are subject to change based on newly emerging data and/ or evidence, which could lead to changes in some or all projections presented in this presentation. We disclaim any responsibility to update these projections in the event of such changes at any time in the future.

Potential of ACT

Orphan Diseases	7000
Pipeline	<ul style="list-style-type: none"> • 5 – 10¹ candidates potentially enter clinical trials each year • Expect 1st clinical asset¹ in 2020 and cumulatively 4 clinical assets¹ by 2023
Potential Asset Pipeline Valuation	<ul style="list-style-type: none"> • Projected mid-range value at US\$42 billion¹ by 2023
Clinical Development Costs (Wet-lab, Phase 2, Phase 3)	<ul style="list-style-type: none"> • US\$ 33 million² per cancer drug • US\$ 120 million accumulated development costs by 2023
Return on Invested Capital	<ul style="list-style-type: none"> • Per drug candidate: 4x to 5x¹ (over 4 years) • Perpetual pipeline: Systematic pipeline of clinical assets targeting orphan diseases and unmet medical needs!

APM Stock Performance (as of 27/5/2019)



Stock chart extracted from <https://www.nasdaq.com/symbol/apm/interactive-chart>

DISCLAIMER

Certain information included in this presentation and other statements or materials published by Aptorum Group Limited (the “Company”) are not historical facts but are forward-looking statements.

These forward-looking statements refer in particular to the Company’s management’s business strategies, its expansion and growth of operations, future events, trends or objectives and expectations, which are naturally subject to risks and contingencies that may lead to actual results materially differing from those explicitly or implicitly included in these statements. Forward-looking statements speak only as of the date of this presentation and, subject to any legal requirement, the Company does not undertake to update or revise the forward-looking statements that may be presented in this document to reflect new information, future events or for any other reason and any opinion expressed in this presentation is subject to change without notice. Such forward looking statements are for illustrative purposes only. Forward-looking information and statements are not guarantees of future performances and are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company. These risks and uncertainties include among other things, the uncertainties inherent in research and development of new products, including future clinical trial results and analysis of clinical data (including post-marketing data), decisions by regulatory authorities, such as the Food and Drug Administration or the European Medicines Agency, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates.

A detailed description of risks and uncertainties related to the Company’s activities is included under the “Risk factors” section of the Company’s Form 20-F and other filings that Aptorum Group may make with the SEC in the future. This presentation contains statistics, data and other information relating to markets, market sizes, market shares, market growth, market positions and other industry data pertaining to the Company’s business and markets. Such information is based on the Company’s analysis of multiple internal and third party sources, including information extracted from market research, governmental and other publicly available information, independent industry publications and information and reports. The Company, its affiliates, shareholders, directors, officers, advisors, employees and representatives have not independently verified the accuracy of any such market data and industry forecasts. Such data and forecasts are included in this presentation for information purposes only.

This presentation does not contain or constitute an offer of securities for sale or an invitation or inducement to invest in securities in the United States or any other jurisdiction. This presentation includes only summary information and does not purport to be comprehensive. No reliance should be placed on the accuracy or completeness of the information or opinions contained in this presentation.



APTORUM GROUP LIMITED

investor.relations@aptorumgroup.com

T +852 2117 6611

F +852 2850 7286
